Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Guliz Ozgun
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07338981CT.gov The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | — | Not Yet Recruiting | — | — | — |
NCT07401875CT.gov A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) | — | Recruiting | — | — | — |
NCT06934057CT.gov Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT06364631CT.gov CARE1 Pragmatic Clinical Trial | — | Recruiting | — | — | — |
NCT05239533CT.gov Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT05215470CT.gov CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | — | Active Not Recruiting | — | — | — |
NCT04322955CT.gov CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | — | Active Not Recruiting | — | — | — |
NCT03065179CT.gov SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients | — | Completed | — | — | — |
NCT02293980CT.gov A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | — | Active Not Recruiting | — | — | — |
Show 1 more trialShow fewer
NCT02118337CT.gov A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Guliz Ozgun | Approved | BB · 66 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →